POEM represents a major advance in achalasia therapy. Nevertheless, given the rarity
of achalasia, there is dearth of high quality long-term data. In 2009 we performed
the 1st POEM outside Japan and currently have the highest single operator volume in
the US. As such our center is now in a position to offer long-term data from a large
cohort of patients. Furthermore, despite the fact that 38% of our patients are out-of-state,
we have been able to collect objective data from a large number of pts to supplement
commonly used subjective scores (Eckardt, GERD).
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gastrointestinal EndoscopyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2017 Published by Elsevier Inc.
